Table 3.
Pathway enrichment by IPA for the overlapped gene profile that is altered in GSK343-treated HepG2 and PLC5 cells
| Pathway | Genes in Pathway | Ratio | p-value |
|---|---|---|---|
| Superpathway of Cholesterol Biosynthesis | EBP, HMGCS1, NSDHL, ACAT2, FDPS, HMGCR, SC5D, MSMO1, LSS, SQLE, IDI1, HSD17B7, CYP51A1, MVD, DHCR7 | 15/28 (53.6%) | < 0.0001 |
| Cholesterol Biosynthesis I | EBP, LSS, NSDHL, SQLE, HSD17B7, CYP51A1, SC5D, MSMO1, DHCR7 | 9/13 (69.2%) | < 0.0001 |
| Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) | EBP, LSS, NSDHL, SQLE, HSD17B7, CYP51A1, SC5D, MSMO1, DHCR7 | 9/13 (69.2%) | < 0.0001 |
| Cholesterol Biosynthesis III (via Desmosterol) | EBP, LSS, NSDHL, SQLE, HSD17B7, CYP51A1, SC5D, MSMO1, DHCR7 | 9/13 (69.2%) | < 0.0001 |
| Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) | HMGCS1, IDI1, FDPS, ACAT2, HMGCR, MVD | 6/17 (35.3%) | < 0.0001 |
Top 5 canonical pathways were shown.